可孚醫療(301087.SZ):收到2項醫療器械註冊證和2項醫療器械註冊變更文件
格隆匯11月16日丨可孚醫療(301087.SZ)公佈,公司於近日收到湖南省藥品監督管理局頒發的2項《醫療器械註冊證》和2項《醫療器械註冊變更文件》。
其中,指夾式脈搏血氧儀“湘械注準20212071990”及胃幽門螺桿菌快速檢測試紙(幹化學法)“湘械注準20212401917”為公司新獲批的註冊證;血糖試紙“湘械注準20202401012”及血糖分析儀“湘械注準20202220977”為已取得的醫療器械註冊證的變更。
公司表示,此次醫療器械註冊證的取得和變更,進一步豐富了產品的品類,是對公司現有檢測產品的有效補充,不斷滿足市場需求,增強了公司產品的整體競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.